ClinicalTrials.gov
public full text
Public Domain
Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC
The purpose of this study is to investigate the ability of alvimopan to reduce the time to return of bowel function in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Half of the participants will receive alvimopan or and half will receive placebo immediately before and for up to seven days after surgery.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Functional and Participation Outcomes of Colorectal Cancer With Peritoneal Metastasis and Pseudomyxoma Peritonei Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC): A Cross-Sectional Survivorship Study.#378574
- Efficacy of Hyperthermic Intraperitoneal Chemotherapy#842708
- mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer#837366
- HIPEC Using High Intra-abdominal Pressure#995601
- Effect Of Celecoxib On Hip Osteoarthritis (OA) Progression#1115317
Record · ID 1086665
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive